BioMarin Announces Third Quarter 2015 Financial Results and Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
BioMarin Pharma (BMRN) Tops Q3 EPS by 5c; Raises Outlook
October 29, 2015 4:06 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.60), $0.05 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $208.9 million versus the consensus estimate of $216.61 million.
BioMarin Pharma sees FY2015 revenue of $880-900 million, versus prior guidance of $850-880 million and the... More
